Castle Biosciences to Participate in Upcoming Investor Conferences
05 Setembro 2023 - 8:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that Derek Maetzold, president and chief executive
officer, and Frank Stokes, chief financial officer, are scheduled
to present a company overview at Baird’s 2023 Global Healthcare
Conference on Wednesday, Sept. 13, 2023, at 10:15 a.m. Eastern
time.
A live audio webcast of the Company’s presentation will be
available by visiting Castle Biosciences’ website at
https://ir.castlebiosciences.com/events-presentations/default.aspx.
A replay of the webcast will be available following the conclusion
of the live broadcast.
Castle will also be available for one-on-one investor meetings
during the 7th Annual Lake Street Best Ideas Growth (BIG7)
Conference on Sept. 14, 2023. Meetings may be requested exclusively
through Lake Street Capital Markets.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905299326/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024